scholarly journals Comparison of methods for in vitro testing of susceptibility of porcine Mycoplasma species to antimicrobial agents.

1991 ◽  
Vol 35 (2) ◽  
pp. 228-233 ◽  
Author(s):  
E A Ter Laak ◽  
A Pijpers ◽  
J H Noordergraaf ◽  
E C Schoevers ◽  
J H Verheijden
Keyword(s):  
Antimicrobial Agents ◽  
Mycoplasma Species ◽  
In Vitro Testing ◽  
Comparison Of Methods

In Vitro Testing of Antimicrobial Agents

2011 ◽  
pp. 1116-1128
Author(s):  
Michael B. Smith ◽  
P. Rocco LaSala ◽  
Gail L. Woods
Keyword(s):  
Antimicrobial Agents ◽  
In Vitro Testing

In vitro activities of acetylmidecamycin and other antimicrobials against human macrolide-resistant Mycoplasma pneumoniae isolates

2020 ◽  
Vol 75 (6) ◽  
pp. 1513-1517 ◽  
Author(s):  
Na Wang ◽  
Yunheng Zhou ◽  
Hong Zhang ◽  
Yang Liu
Keyword(s):  
Mycoplasma Pneumoniae ◽  
Antimicrobial Agents ◽  
Mycoplasma Hominis ◽  
Clinical Isolates ◽  
Mycoplasma Species ◽  
Broth Microdilution ◽  
Microdilution Method ◽  
Broth Microdilution Method ◽  
Ureaplasma Spp

Abstract Objectives To assess the in vitro activities of acetylmidecamycin, a 16-membered macrolide, and 11 other antimicrobial agents against human mycoplasmas. Methods A total of 187 clinical isolates, Mycoplasma pneumoniae (n = 110), Mycoplasma hominis (n = 26) and Ureaplasma species (n = 51), were included in this study. The MICs of 12 antimicrobial agents, including acetylmidecamycin, thiamphenicol, chloramphenicol and some other macrolides, fluoroquinolones and tetracyclines, for these clinical isolates were determined by the broth microdilution method. Results For M. pneumoniae, the MIC90 values of the tested macrolides were: acetylmidecamycin (1 mg/L)<josamycin (4 mg/L)<midecamycin (8 mg/L)<azithromycin (16 mg/L)<erythromycin (>128 mg/L). Thiamphenicol and chloramphenicol had the same MIC90 (2 mg/L). For Ureaplasma species, the MIC90 values were: acetylmidecamycin (0.25 mg/L)<josamycin (0.5 mg/L)=midecamycin<azithromycin (1 mg/L)=erythromycin. Chloramphenicol had a lower MIC90 (2 mg/L) than that of thiamphenicol (4 mg/L). For M. hominis, the MIC90 values were: acetylmidecamycin (0.25 mg/L)<josamycin (0.5 mg/L)<midecamycin (2 mg/L)<azithromycin (>128 mg/L)=erythromycin. The MIC90 values of chloramphenicol and thiamphenicol were 2 and 4 mg/L, respectively. Conclusions The results indicated that acetylmidecamycin and thiamphenicol are active in vitro against the most common mycoplasma species infecting humans, including those resistant to macrolides and fluoroquinolones. Acetylmidecamycin and thiamphenicol might be a promising option for clinicians to treat infections caused by Mycoplasma and Ureaplasma spp., particularly macrolide-resistant M. pneumoniae in paediatrics and fluoroquinolone-resistant M. hominis in adults. Further investigation of their clinical roles in treating infections caused by these organisms is warranted.

scholarly journals In Vitro Activity of BAY 12-8039, a New Fluoroquinolone, against Mycoplasmas

1998 ◽  
Vol 42 (3) ◽  
pp. 703-704 ◽  
Author(s):  
C. M. Bébéar ◽  
H. Renaudin ◽  
A. Boudjadja ◽  
C. Bébéar
Keyword(s):  
Antimicrobial Agents ◽  
Ureaplasma Urealyticum ◽  
Vitro Activity ◽  
Mycoplasma Species ◽  
In Vitro Activity

ABSTRACT The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30 strains ofUreaplasma urealyticum was compared with those of three other antimicrobial agents. BAY 12-8039 at 0.5 μg/ml inhibited 100% of all the mycoplasmal and ureaplasmal strains tested. The minimal bactericidal concentrations of BAY 12-8039 increased only two- to eightfold compared to the MICs. Furthermore, they were comparable to those of sparfloxacin and lower than those of doxycycline and clarithromycin.

scholarly journals Haemophilus influenzae: antibiotic susceptibility.

1988 ◽  
Vol 1 (2) ◽  
pp. 218-227 ◽  
Author(s):  
C A Needham
Keyword(s):  
Haemophilus Influenzae ◽  
Genetic Information ◽  
Antibiotic Susceptibility ◽  
Antimicrobial Agents ◽  
Invasive Disease ◽  
In Vitro Testing ◽  
Principal Mechanism ◽  
Chloramphenicol Resistance ◽  
Treatment Of Infection

Ampicillin resistance was first reported among clinical isolates of Haemophilus influenzae in 1972. Reports of chloramphenicol resistance followed shortly thereafter. The principal mechanism of resistance to these two antibiotics is enzymatic. Although other mechanisms have been described, they are found in comparatively few strains. The genetic information for the inactivating enzymes is plasmid mediated and therefore readily transmissible to susceptible strains. Consequently, effective therapy for invasive disease caused by this pathogen has been seriously compromised. As antibiotic susceptibility became less predictable, in vitro testing became increasingly important. Unfortunately, the standardization of methods for laboratory testing has been slow and complicated by the fastidious nature of the organisms. This review traces the development of antibiotic resistance in H. influenzae, discusses the mechanisms which appear to be important in mediating resistance, explores newer antimicrobial agents which might be useful in the treatment of infection, and analyzes the various approaches to in vitro testing.

Urokinase Evaluated with the Experimental Radioactive Embolus

1967 ◽  
Vol 17 (03/04) ◽  
pp. 405-411
Author(s):  
M Hume
Keyword(s):  
Animal Experiment ◽  
Blood Clot ◽  
In Vitro Testing ◽  
Effective Agent

SummaryUrokinase and urokinase-activated plasmin have been given to the dog and rabbit. A thrombolytic state has been induced. Purified urokinase has induced lysis of the experimental radioactive blood clot embolus in the circulation. Demonstration of effectiveness in this animal experiment is hampered by inhibition of the agents in the circulation to a degree much greater than was noted in previous experiments with streptokinase. In vitro testing indicates that under proper conditions urokinase will be an effective agent in the treatment of human thromboembolism.

Preliminary in Vitro Investigations on The Inhibitory Activity of The Original Dietary Supplement Oxidal® on Pathogenic Bacterial Strains

2020 ◽  
Vol 11 ◽  
pp. 37-43
Author(s):  
Prof. Teodora P. Popova ◽  
Toshka Petrova ◽  
Ignat Ignatov ◽  
Stoil Karadzhov
Keyword(s):  
Dietary Supplement ◽  
Broad Spectrum ◽  
Pathogenic Bacteria ◽  
Antimicrobial Agents ◽  
Clinical Effectiveness ◽  
Inhibitory Effect ◽  
Diffusion Method ◽  
Bacterial Strains ◽  
Microbial Strains

The antimicrobial action of the dietary supplement Oxidal® was tested using the classic Bauer and Kirby agar-gel diffusion method. Clinical and reference strains of Staphylococcus aureus and Escherichia coli were used in the studies. The tested dietary supplement showed a well-pronounced inhibitory effect against the microbial strains commensurable with that of the broad-spectrum chemotherapeutic agent Enrofloxacin and showed even higher activity than the broad spectrum antibiotic Thiamphenicol. The proven inhibitory effect of the tested dietary supplement against the examined pathogenic bacteria is in accordance with the established clinical effectiveness standards for antimicrobial agents.

Sign in / Sign up

Export Citation Format

Share Document